The FDA just gave Agios Pharmaceuticals a big reason to celebrate. The agency accepted the company's application for mitapivat, an oral drug for sickle cell disease, and granted it Priority Review. That means the review timeline gets cut from the standard 10 months down to six, with a decision deadline set for November 1.

Investors liked what they heard. Shares of Agios (AGIO) jumped more than 15% on Tuesday, hitting $43.18 by the time of publication.

What's Mitapivat, and Why Does It Matter?

Mitapivat is an oral pyruvate kinase (PK) activator. It's already approved in the U.S. for two other conditions: pyruvate kinase deficiency (approved in 2022) and thalassemia (approved in 2025). Now Agios is aiming for a third indication—sickle cell disease—and the FDA is giving it a fast track.

The application is based on data from the RISE UP Phase 2 and Phase 3 trials, which studied mitapivat in patients aged 16 and older with sickle cell disease. The FDA's Priority Review designation is reserved for drugs that could offer significant improvements in safety or efficacy for serious conditions, so this is a strong signal that the agency sees potential here.

Wall Street Weighs In

Analysts are feeling optimistic. Truist Securities raised its price target from $36 to $41, keeping a Buy rating. Analyst Gregory Renza noted that investor attention has been focused on Agios' push for accelerated approval using hemoglobin as a surrogate endpoint. He added that the FDA's ongoing review, combined with new RISE UP transfusion-burden data presented at the European Hematology Association Congress, reduces risk for the confirmatory REIGNITE study.

Bank of America Securities also bumped its target, from $40 to $46, and reiterated its Buy rating. RBC Capital was a bit more cautious, maintaining its Sector Perform rating but raising its target from $28 to $32.

Overall, Wall Street has a Buy consensus on the stock, with an average price target of $39.71 based on 12 analysts. Forecasts range from $31 to $50.

Technical Picture: Strong Momentum, But Watch for Pullback

AGIO is trading well above its major moving averages. The stock sits 25.4% above its 20-day simple moving average of $34.24 and 35.1% above its 200-day simple moving average of $31.77. The 20-day moving average is above the 50-day, signaling a bullish short-term trend. However, the 50-day average is still below the 200-day following a death cross formed in December 2025.

The Relative Strength Index (RSI) is at 84, which puts the stock in overbought territory. That means momentum is strong, but it also increases the risk of a short-term pullback or consolidation. Key resistance is near $44, just below the 52-week high of $46. Initial support is around $39.

What's Next?

Investors are also looking ahead to the company's second-quarter earnings report, scheduled for July 30. Analysts expect a loss of $1.71 per share on revenue of $25.64 million. In the same quarter last year, Agios reported a loss of $1.93 per share on revenue of $12.46 million.

For now, all eyes are on November 1. If the FDA gives mitapivat the green light for sickle cell disease, it could be a game-changer for Agios—and for patients living with the condition.